Molnupiravir: From Hope to Epic Fail?
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far. However, it has recently been associated with very poor clinical efficacy, the risk of creating novel SARS-CoV-2 varia...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2022-11-01
|
| Serija: | Viruses |
| Teme: | |
| Online dostop: | https://www.mdpi.com/1999-4915/14/11/2560 |
| Oznake: |
Brez oznak, prvi označite!
|